Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068130 · ClinicalTrials.gov registry record · Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 261
- Enrollment target
NCT03068130 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 261 participants.
The verdict
NCT03068130, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 261 participants
- Enrollment target
Study Summary
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
Interventions
- DRUG Bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2017-04-18 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068130
The ClinicalTrials.gov registry entry for NCT03068130 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bardoxolone methyl is the first listed.
NCT03068130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03068130 about?
NCT03068130 is a clinical study titled "Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER". This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
What is the current status of trial NCT03068130?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2017-04-18. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT03068130?
The interventions under investigation include: Bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT03068130?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.